pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,258 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1044Endpoints792BioPharma Dive304BioSpace225Fierce Biotech213onclive165raps78globenewswire health
therapy area
allOncology6172Rare Disease1500Cardiology1118Hematology1055Immunology1034Vaccines939Pulmonology
  • Rep. Tom Kean Jr. Discloses Depression Diagnosis After Four-Month Congressional Absence
    Rep. Tom Kean Jr., a Republican congressman from New Jersey, announced on the House floor that he has been receiving treatment for depression, which explains his unexplained four-month absence from…
    STAT · 1mo agoNeutral↗ source
  • Virtual mental-health firms accelerate AI chatbot development using therapy session data
    People are turning to artificial intelligence for daily tasks, companionship and emotional support, prompting virtual mental‑health providers to explore AI solutions. Companies that were previousl…
    Endpoints · 1mo agoNeutral↗ source
← prev
page 48 of 91
next →
73
fda recalls49
fda medwatch45
fda press28
923
Psychiatry & CNS741
Ophthalmology432
Pain413
Endocrinology & Metabolism395
Infectious Disease373
Florida mandates EKGs for high-school athletes, but the new law may cause stress and cost
Florida has become the first state to require electrocardiograms for high‑school athletes before they can participate in sports. The law is intended to screen for hidden heart conditions that could…
STAT · 1mo agoRegulatoryNegative↗ source
  • FDA acting director of cell and gene therapies Vijay Kumar to depart his post
    Vijay Kumar, who has been serving as the acting director of the Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products, announced he will leave his position. In an inte…
    Endpoints · 1mo agoNeutral↗ source
  • Nominations Open for 2026 Endpoints 11 Biotech Awards
    Nominations for the 2026 Endpoints 11 awards are now being accepted, with submissions due by July 15. The awards target private biotech startups that have differentiated science, strong leadership…
    Endpoints · 1mo agoNeutral↗ source
  • Student loan cap policy favors chiropractic over critical health professions, warns surgeon
    David S. Shapiro, a board-certified surgeon and physician executive, argues that the Education Department's new student-loan limits miss the realities of modern health care. The rule caps annual f…
    STAT · 1mo agoRegulatoryNegative↗ source
  • STAT+: FDA’s top gene therapy regulator is leaving his role
    The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
    STAT · 1mo ago↗ source
  • NEJM retracts pivotal data for Amgen's Tavneos
    Pivotal data for Amgen’s Tavneos have been retracted from the New England Journal of Medicine, creating another obstacle for the beleaguered autoimmune drug. Two academic authors requested the retr…
    Endpoints · 1mo ago↗ source
  • STAT+: AstraZeneca to pay $34 million to settle kickback charges filed by Texas attorney general
    AstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks to improperly influence prescriptions paid for by Texas Medicaid.
    STAT · 1mo ago↗ source
  • STAT+: 26 states sue to block Medicaid work requirements
    States argue the rules will make it too hard for people to get the Medicaid coverage they're entitled too.
    STAT · 1mo ago↗ source
  • John Reed on J&J’s R&D model, oncology deals and pipeline expansion potential
    John Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California's Sanford Burnham medical research institute 13 years ago, giving him unique insight into h…
    Endpoints · 1mo ago↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 1mo ago↗ source
  • EU lobby urges member states to improve Europe’s life sciences sector
    More than 200 biopharma investors and firms have signed an open letter calling for European governments to improve Europe’s life sciences sector. The Friday letter was addressed to EU member states…
    Endpoints · 1mo ago↗ source
  • STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a ‘forced’ McKinsey collaboration
    Who controls the Medicaid market, GLP-1 usage and pizza household costs, and more from Health Care Inc.
    STAT · 1mo ago↗ source
  • STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
    The panel will soon consider whether to relax restrictions on certain peptides.
    STAT · 1mo ago↗ source
  • Zymeworks CEO on why the Theravance deal is value for money
    On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
    Endpoints · 1mo ago↗ source
  • BioCryst ends internal discovery programs, will close Alabama research facility
    BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal disc…
    Endpoints · 1mo ago↗ source
  • Evommune's lead drug fails in chronic hives, stock sinks
    Evommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin condit…
    Endpoints · 1mo ago↗ source
  • Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
    Plus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisitio…
    Endpoints · 1mo ago↗ source
  • Post-Hoc: China deals are pharma’s new tax inversions
    About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...
    Endpoints · 1mo ago↗ source
  • Theravance, after clinical setbacks, agrees to $929M buyout
    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
    BioPharma Dive · 1mo ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 1mo ago↗ source
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    BioPharma Dive · 1mo ago↗ source
  • FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
    BioPharma Dive · 1mo ago↗ source
  • At BIO, tension over China biotech deal regulation looms
    Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
    BioPharma Dive · 1mo ago↗ source